A Phase 1 study of Durvalumab (MEDI4736) plus Tremelimumab in Combination with Platinum-based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer and Performance Status 2
Categories (click each to see list of all clinical trials associated with that category): Lung/Thoracic
Current Status: Open to accrual
Phase: I (Cancer Control)
Principal Investigator: Ganti, Apar
Contact Information:
Brandie Booker, RN
402-559-8197
brandie.booker@unmc.edu
Eligibility: https://www.clinicaltrials.gov/ct2/show/NCT03963414?cond=NCT03963414&draw=2&rank=1#eligibility
Summary